Our Board

Meet icare's Board of Directors

The Board is accountable to Government through the Minister responsible for icare, as outlined in the allocation of acts.

The Board is a governing Board and all decisions relating to the functions of icare are to be made by or under the authority of the Board, including the appointment of the CEO. The CEO is a Director of the Board as well as Chief Executive of each Authority. The Board has ultimate authority over icare's management and has delegated the day to day operations of the organisation to the CEO. The Board has delegated certain functions and responsibilities to its Committees as well as the CEO to assist in the oversight of the organisation and discharge of its responsibilities.

In addition to appointing the Board, the Minister along with the Treasurer approves icare's annual Statement of Corporate Intent. The Minister may also give the Board written direction if it is in the public interest to do so after consulting with the Board.

The Board, consisting of eight Non-Executive Directors and the Chief Executive Officer, was appointed by the Minister under the State Insurance and Care Governance Act 2015.

The Non-Executive Directors are highly skilled and bring extensive experience to icare including insurance, customer experience, transformation, financial and investment management, healthcare, disability and care services, technology/digital and strategy.

As a governing Board, the objectives of the Board are to provide leadership and to determine and monitor:

  • the strategic direction, organisational objectives including the progress and performance of their implementation
  • the policy framework and icare's general policies, providing direction to the CEO and governing the organisation's operations.
The Board has established four committees to assist it with its oversight and governance responsibilities. The Investment and Asset Committee, People and Remuneration Committee, the Board Audit Committee and the Board Risk Committee, each chaired by a Non-Executive Director of the Board.

The Board and its Committees have established charters that outline their responsibilities as required by NSW Treasury's Commercial Policy Framework and the NSW Government's Guidelines for Boards and Committees.

Meet icare's Board of Directors

    Board communiqués

  • February 2024

    In February 2024, we held an Investment and Asset Committee, a People and Remuneration Committee, a Board Audit Committee, a Board Risk Committee, and our Board meeting. Our new Board members, Leah Fricke, and Mark Morey joined us for their first icare Board meeting.

    The composition of our committees has changed slightly. Leah Fricke was appointed Chair of the Board Audit Committee and Member of the Board Risk Committee, while Mark Morey has joined the Investment and Asset Committee as a Member. Kirsten Armstrong joins the People and Remuneration Committee as a Member.

    At the Board meeting, the Board received the Work Health and Safety Due Diligence Report, the CEO report (which included the Actuarial Monitoring Report), the Chief Risk Officer’s Report, and the Chief Financial Officer’s report which all provided updates from Management on relevant matters.

    The Board heard from a representative from Promontory Australia, the Independent Assurer on the progress of icare’s Improvement Program. It was pleasing to hear that a total of 67 (of 107) recommendations have been closed to date and work continues to close off the remaining recommendations. A copy of Promontory’s Ninth Quarterly Update Report to icare is available on our website for viewing.

    The Board approved the Nominal Insurer premium filing for 2024/25, the Workers Compensation Dust Diseases Authority Target Contribution requirement and funding to the Asbestos and Dust Diseases Research Institute for the purpose of providing essential research and practical support for individuals affected by silicosis.

    The Board discussed and noted several updates including on the NSW Treasury Expense Review, the Net Asset Holding Level Policy Contributions for Insurance for NSW and the SIRA Treasury Managed Fund Review.

  • November 2023

    At the icare Board meeting held on Monday 27 November 2023 at 321 Kent Street, Sydney, the Board received the Work Health and Safety Due Diligence Report, CEO report(which included the Actuarial Monitoring Report) and CRO Report, which all provided updates from Management on relevant matters.

    The Board received a progress update on the Enterprise Improvement Program, the Nominal Insurer Improvement Program, and had a discussion with the Independent Assurer, Promontory, ahead of the release of their Eighth Quarterly Update. A copy of the update is available on the icare website under the heading ‘Improvement at icare’.

    Key items on the agenda included the TMF Workers Compensation 2025 Claims Service Provider Procurement Strategy, Dust Diseases Authority Fund Investment Review, FY24-FY33 Half Year Review of Budget and discussion on the outcome of the Request for Proposal for Reinsurance Services. After a good discussion, the Board approved all four items.

    The Board also approved several Policies as endorsed by the Board Audit and Board Risk Committees.

    The Board received updates from Management on the status of the Cyber Uplift Program, the Performance Audit being conducted by the Audit Office and received a live demonstration of the published Claims Service Provider Performance on the icare website. The Board found the live demonstration very insightful and commended Management on the progress and outcomes.

    The Board discussed with NSW Treasury and TCorp representatives the objectives and proposed timelines of the Whole of Government Investment Fund.

    Lastly, the Board received an update on the key discussions that took place at the relevant Board Sub-Committees during November, being the Board Audit Committee, Board Risk Committee, Investment and Asset Committee and the People and Remuneration Committee.

  • October 2023

    The icare Board met on Monday, 30 October 2023 at 321 Kent Street, Sydney.

    Prior to the meeting commencing, the Board had a session with The Hon Sophie Cotsis, Minister for Industrial Relations and Work Health and Safety, and Tom Craven, Senior Policy Advisor, where priority matters relating to icare were discussed.

    The Board then received the Work Health and Safety Due Diligence Report, the CEO report and CRO Report, which all provided updates from Management on relevant matters.

    The Board also received a progress update on the Enterprise Improvement Program and the Nominal Insurer Improvement Program, outlining the progress in addressing the McDougall and GAC Recommendations.

    The key items on the agenda included consideration of the FY24-FY33 Half Year Review of Budget, Investment Strategy, and the 2023 Customer Service Conduct Principles Attestation. After a good discussion, the Board approved all three items.

    The Board then received an update on the proposed Whole of Government Investment Fund, the activities of the Customer Advocate across the three areas of governance, advocacy and resolution, and the outcomes of the 2023 culture and engagement surveys.

    Finally, the Board also received an update on the key discussions that took place at the relevant Board Sub-Committees during October, being the Investment and Asset Committee.

  • September 2023

    At the icare Board meeting held on Monday 25 September 2023 at 321 Kent Street, Sydney, the Board received the Work Health and Safety Due Diligence Report, CEO report (which included the Actuarial Monitoring Report) and CRO Report, which all provided updates from Management on relevant matters.

    The Board also received a progress update on the Enterprise Improvement Program and the Nominal Insurer Improvement Program, including an update from the Independent Assurer, Promontory following the release of their Seventh Quarterly Update. A copy of the update is available on the icare website.

    The key items on the agenda included the Financial Condition Report, the 2022/23 Year-end Financial Statements, Final FY2023-24 Enterprise Scorecard, and consideration of options for undertaking Actuarial Valuation. After a good discussion, the Board approved all four items.

    The Board also approved the Nominal Insurer Business Plan and Home Builders Compensation Fund Business Plan, both of which need be submitted to the State Insurance Regulatory Authority. Several policies as well as Amendments to Part 1 of the Lifetime Care and Support Guidelines 2018 were also approved.

    The Board received an update on the progress of icare’s customer experience maturity against the six pillars of customer centricity and took a deep dive into our customer understanding. This included an experiential session where the Board had the opportunity to walk the floor and view scheme customer experience artefacts for Insurance for NSW, Nominal Insurer (Workers Compensation) and Lifetime Schemes, while engaging with Staff. The Board then received an update on the icare brand strategy development and brand uplift.

    The Board found this exercise very insightful and acknowledged the different stages of maturity across the Schemes.

    The Board discussed the draft Annual Report, TMF Workers Compensation 2025 Claims Service Provider Procurement Strategy and the Market Allocation Model, providing feedback for Managements consideration,

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during September, being the Board Risk Committee, Board Audit Committee, People and Remuneration Committee, and the Dust Diseases Board.

  • August 2023

    At the icare Board meeting held on Monday 28 August 2023 at 92-100 Donnison Street, Gosford, the Board received the Work Health and Safety Due Diligence Report (WHS Report), CEO report and CRO Report, which all provided updates from Management on relevant matters.

    The Board also received a progress update on the Enterprise Improvement Program and the Nominal Insurer Improvement Program.

    The Board noted the submission to Treasury of the FY2023-24 to FY2032-34 forecasts for Self-Insurance Corporation and the Dust Diseases Authority.

    Key items on the agenda included the Final FY2023-24 Statement of Business Intent and Business Plan, the Internal Audit and Risk Management Attestation Statement as well as the NSW Cyber Security Policy Annual Report Attestation Statement. After a good discussion, the Board approved all three items.

    The Board also approved levies for Lifetime Care and Support and Motor Accident Injury Treatment and Care Benefits, the HBCF Premium Filing addendum as requested by SIRA and several policies.

    The Board discussed the proposed icare Investment Strategy, Market Share Allocation Policy as well as the draft NI and HBCF Business Plans and provided feedback on the documents for Managements consideration.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during August, being the Investment and Asset Committee, the People and Remuneration Committee, the Board Audit Committee, and the Board Risk Committee.

    During the day, the Board participated in a call monitoring session facilitated by the Claims Support Services Team, who are the frontline claims management function for both the Nominal Insurer and Treasury Managed Fund workers insurance. Each Director had the opportunity to monitor incoming calls that came through the Claims Support Service queue or dedicated outgoing calls Case Managers made to the participants in their portfolio. The Board found this exercise very insightful and acknowledged the engagement, experience, and passion of the Case Managers.

    Finally, to build closer connections between the Board and Teams across icare, the Board participated in employee engagement activities, which included having a casual lunch and afternoon tea with the staff present at the Gosford office.

  • July 2023

    The Board received the Work Health and Safety Due Diligence Report (WHS Report), CEO report and CRO Report, which all provided updates from Management on relevant matters. The Board also received the CFO Report, which included the Insurance Liability Valuation Results.

    The Board received a progress update on the Enterprise Improvement Program and the Nominal Insurer Improvement Program.

    The Board approved the execution of the Investment Services Agreement between icare and TCorp and the proposed Master Financial Services Agreement fees for FY2024 and FY2025.

    The Board approved the Home Building Compensation Fund (HBCF) Business Case, Data Governance Framework and a Salesforce Contract extension until 30 June 2024.

    The Board held a deep dive on customer, received an update from the Customer Advocate, and the work currently happening in the Innovation and Partnerships Team.

    The Board received an update on the recent culture and engagement survey results as well as on key discussions that took place at the relevant Board Sub-Committees during June.

    The Board noted the Governance Report.

  • May 2023

    The Board received the Work Health and Safety Report (WHS Report), CEO report and CRO Report, which all provided updates from Management on relevant matters.

    The Board received a progress update on the Enterprise Improvement Program and the Nominal Insurer Improvement Program., including an update from the Independent Assurer, Promontory.

    The Board approved the Dust Diseases Care Transformation Program Business Case, the Treasury Managed Fund (TMF) Workers Compensation Transformation Business Case and the Home Building Compensation Fund (HBCF) Distribution.

    The Board approved the final Budget, Statement of Business Intent (SBI) and Business Plan, including their submission to NSW Treasury.

    The Board approved the Risk Appetite Statement, FY23/24 Internal Audit Plan and several Policies.

    The Board received an update on the Catholic Church Insurance announcement that they would no longer be providing workers compensation insurance in NSW from 29 June 2023.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during May, being the Investment and Asset Committee, the People and Remuneration Committee, the Board Audit Committee, and the Board Risk Committee.

    The Board noted the Governance Report.

  • March 2023

    The Board received the CEO report, CRO Report and Work Health and Safety Due Diligence Report (WHS Report), which all provided updates from Management on relevant matters.

    The Board received a progress update on the Enterprise Improvement Program and the Nominal Insurer Improvement Program.

    The Board approved the Premium Filing with SIRA for the Nominal Insurer Premium Filing 2023/24.

    The Board approved the Indexation Remediation for the Nominal Insurer and Treasury Managed Fund (TMF) and granted procurement approval for Application Delivery and Support Services Tender.

    The Board received an update on the requirements for the Preliminary FY2023-24 Statement of Business Intent (SBI) and Business Plan (BP), and Preliminary FY24-FY33 Budget.

    The Board held a session with Simon Cohen, Independent Review Officer, which included updates from both the icare Board and Simon Cohen.

    The Board received updates on the Dust Diseases Care Transformation Program and TMF Workers Compensation Transformation Program.

    The Board discussed the Quarterly Customer Advocate Report and took a deep dive into Customer.

    The Board noted the Governance Report.

  • February 2023

    The Board noted the Board Performance Evaluation Report, reviewed its Board Committee Structure and Composition and approved the revised Board and Committee Charters.

    The Board received the Work Health and Safety (WHS) Report, CEO report, CFO report and the CRO Report, which all provided updates from Management on relevant matters.

    The Board received a progress update from Promontory on the Enterprise Improvement Program and the Nominal Insurer Improvement Program.

    The Board approved the Premium Filing with SIRA for the Home Building Compensation Fund and the Dust Diseases Care Levy.

    The Board approved the Reinsurance Management Strategy and FY24 Placement and the Lifetime Care & Support Authority Fund Investment Strategy Review.

    The Board held a session with NSW Treasury Secretary, Dr Paul Grimes, which included updates from both the icare Board and Dr Grimes.

    The Board approved several revised policies and the decommissioning of the Purchase to Pay policy.

    The Board noted the Quarterly Regulator Report, icare Stakeholder update and the Cybersecurity Communications Strategy.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during February, being the Investment & Asset Committee, People and Remuneration Committee, Board Audit Committee and Board Risk Committee.

    The Board noted the Governance Report and the Significant Litigation Update.

  • November 2022

    The Board received an update on Board Committee Membership. The Board also received the icare Work Health and Safety (WHS) Report (including COVID-19 Management), CEO report, and the CRO Report, which provided updates from management on relevant matters.

    The Board received a progress update from management on the Enterprise Improvement Program and the Nominal Insurer Improvement Program.

    The Board approved the Nominal Insurer Workers Compensation Claims Service Providers extension, the Treasury Managed Fund (TMF) Workers Compensation Claims Service Providers extension and the TMF Investment Strategy Review.

    The Board approved the Biennial icare Investment Strategy Review, a contract variation to Print Managed Services and the icare Brand Review.

    The Board approved several policies as part of its annual policy review and approved the WHS Strategy and Framework and the Governance Assurance Framework.

    The Board received an update on the Dust Diseases Care Business Case, the Quarterly Regulatory Report, and an update on the Independent Review of Nominal Insurer Claims model for icare.

    The Board received a presentation from Professor John Buchanan and John Trowbridge on the findings of the research into meeting the Return to Work challenge. The Board noted the findings and the implications for the Workers Compensation Nominal Insurer and TMF schemes.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during November, being the Investment and Asset Committee, Technology and Data Strategy Committee, People and Remuneration Committee, Board Audit and Board Risk Committees.

    The Board noted the People Matter Employee Survey Results and the Governance Report. 

  • October 2022

    The Board received the icare Work Health and Safety (WHS) Report, CEO report, and the CRO Report, which provided updates from management on relevant matters.

    The Board received a progress update from management on the Enterprise Improvement Program and the Nominal Insurer Improvement Program.

    The Board approved the FY23-32 Half Year Budget Review, the Workers Compensation Insurance Fund Investment Strategy Review and the Dust Diseases Authority Fund Investment Strategy Review.

    The Board approved the State Insurance Regulatory Authority’s Customer Service Conduct Principles Attestation Form.

    The Board received an update on the Nominal Insurer RFP and Claims Model.

    The Board also received the Quarterly Customer Advocate report and an update on the delivery of the Professional Standards Framework and Capability Strategy.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committee during October, being the Investment and Asset Committee.

    The Board noted the Governance Report and the Credit and Counterparty Risk Policy.

  • September 2022

    The Board received the icare Work Health and Safety (WHS) Report, CEO report, and the CRO Report, which provided updates from management on relevant matters.

    The Board received a progress update from management on the Enterprise Improvement Program and the Nominal Insurer Improvement Program.

    The Board approved the FY22 Audited Financial Statements, and the Australian Accounting Standards Board 17 (AASB) Business Case. The Board noted the Financial Condition Report.

    The Board approved the Nominal Insurer Business Plan, Home Building Compensation Fund Business Plan and Lifetime Care and Compulsory Third Party Care levies.

    The Board received the Nominal Insurer RFP and Claims Model update and approved the selection of six Claims and Injury Management Service Providers to manage claims.

    The Board held a joint session with the State Insurance Regulatory Authority (SIRA) Board, which included updates from both the icare CEO and SIRA CEO. The Board and the SIRA Board additionally held a discussion without management being present.

    The Board approved the revised Data Migration Program and the revised Brand Architecture. The Board endorsed the Annual Report Update.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during September, being the Board Audit Committee and Board Risk Committee.

    The Board noted the Governance Report.

  • August 2022

    The Board received the icare Work Health and Safety (WHS) Report, CEO report, CRO Report and the Quarterly Regulatory Report, which provided updates from management on relevant matters.

    The Board received a progress update from management on the Enterprise Improvement Program and the Nominal Insurer Improvement Program.

    The Board approved the updated FY23 Scorecards, People and Culture Strategy, Internal Audit and Risk Management Attestation and NSW Cyber Security Policy Attestation.

    The Board also approved the Procurement Policy, Pricing Policy and the updated business case for the Nominal Insurer Core Platform Uplift Program.

    The Board noted and discussed the enterprise employee engagement survey (act2engage) results, the Draft Nominal Insurer Business Plan and the Draft Home Building Compensation Fund Business Plan.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during August, being the Technology and Data Strategy Committee, Investment and Asset Committee, People and Remuneration Committee, Board Audit Committee and Board Risk Committee.

    The Board noted the Governance Report, and Guidewire Managed Services Update.

    The Board received a presentation by Professor David Lacey from IDCARE on the trends and key issues in cyber security.

  • July 2022

    The Board received the icare Work Health and Safety (WHS) Report, CEO report, CRO Report and CFO Report, which provided updates from management on relevant matters, including the Insurance Liability Valuation results.

    The Board received a progress update from management on the Enterprise Improvement Program and the Nominal Insurer Improvement Program, including an update from the Independent Assurer, Promontory. The Board also received its monthly update on the progress of the Pre-Injury Average Weekly Earnings Remediation Program.

    The Board approved the Compliance Management Policy.

    The Board undertook two deep dives in relation to the improvements made to measuring better outcomes for those we serve and the actual and perceived fairness in a decision-making process.

    The Board received an update on customer advocacy and also data migration.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during July, being the Board Audit Committee and the Board Risk Committee.

    The Board noted the Governance Report, which includes correspondence between the Responsible Minister and icare, a summary of any circular resolutions and the activities undertaken in accordance with Board delegations in the reporting period.

  • May 2022

    The Board received the icare Work Health and Safety (WHS) Report, CEO report and CRO Report, which provided updates from management on relevant matters, including the quarterly Enterprise Performance Scorecard results.

    The Board received a progress update from management on the Enterprise Improvement Program and the Nominal Insurer Improvement Program, including an update from the Independent Assurer, Promontory. The Board also received its monthly update on the progress of the Pre-Injury Average Weekly Earnings Remediation Program, the final report into the Dust Diseases Care Compensation Remediation Program and the quarterly update on icare's relationship with the regulator.

    The Board approved the FY23 icare and Scheme budgets, the FY23 Business Plan and Statement of Business Intent and the FY23 Enterprise Performance Scorecard.

    The Board also approved the updated Risk Appetite Statement, the FY23 Internal Audit Plan and a number of internal policies.

    The Board undertook a deep dive in relation to the Return to Work Performance Program and received an update in relation to the Innovation and Partnerships team (formerly known as the icare Foundation).

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during May, being the Investment and Asset Committee, the People and Remuneration Committee, the Board Audit Committee, the Board Risk Committee and the Technology and Data Strategy Committee. 

  • March 2022

    The Board received the icare Work Health and Safety (WHS) Report, CEO report and CRO Report, which provided updates from management on relevant matters.

    The Board received a progress update from management on the Enterprise Improvement Program (EI) and the Nominal Insurer (NI) Improvement Program, including an update from the Independent Assurer, Promontory. The Board also received its monthly update on the progress of the Pre-Injury Average Weekly Earnings Remediation Program and the Dust Diseases Care Compensation Remediation Program.

    The Board discussed the preliminary FY23-32 budgets for IfNSW & HBCF, the Lifetime Care schemes and the icare service entity, and additionally noted the draft Statement of Business Intent (SBI).

    The Board held a joint session with the State Insurance Regulatory Authority (SIRA) Board, which included updates from both the icare CEO and SIRA CEO. The Board and the SIRA Board additionally held a discussion without management being present. The icare Chair and SIRA Chair noted that it is pleasing to see the continued positive engagement between the icare and SIRA management teams.

    The Board approved the FY2022/23 Reinsurance Management Strategy in respect of its reinsurance program for the Treasury Managed Fund and the Construction Risk Insurance Fund and received an update from management in relation to the Customer Satisfaction metric.

    The Board received a presentation from NSW Treasury representatives related to Climate Risk Management.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during March, being the Investment and Asset Committee and the People and Remuneration Committee.

  • February 2022

    The Board received the icare Work Health and Safety (WHS) Report, CEO report, CRO Report and the Quarterly CFO Report, which provided updates from management on relevant matters.

    The Board received a progress update from management on the Enterprise Improvement Program, including an update from the Independent Assurer, Promontory. The Board also received its monthly update on the progress of the Pre-Injury Average Weekly Earnings Remediation Program and the Dust Diseases Care Compensation Remediation Program and the quarterly update on icare's relationship with the regulator.

    The Board discussed the Insurance Liability Valuation results as appropriate for inclusion in the entity accounts for the Nominal Insurer (NI), Treasury Managed Fund (TMF), Lifetime Care (LTC), Dust Diseases Care (DDC), Home Building Compensation Fund (HBCF), Pre-Managed Fund (PMF) and Motor Accident Injury Treatment and Care Benefits Fund (CTP Care).

    The Board approved the Investment Strategy Review for both the Lifetime Care and Support Authority Fund and the Workers Compensation Insurance Fund. The Board also approved a number of internal policies as part of its annual policy review.

    The Board approved the Lifetime Care and Support Scheme levy, the Motor Accident Injury Treatment and Care Benefits Fund (CTP Care) levy and the Workers Compensation Dust Diseases Authority Contribution for FY2022/23 for submission to the State Insurance Regulatory Authority (SIRA). The Board also approved the NI and HBCF premium filings, to be submitted to SIRA for the policy period commencing 30 June 2022.

    The Board approved the 2021-2026 icare Strategic Procurement Plan and the revised icare Board and Committee Charters as part of the annual Charter review.

    The Board received an update from management on the Quarterly Performance Scorecard Results, the TMF target agency contribution target for FY2022-23 and the NI Claims Service Providers Request for Proposal that is currently underway.

    The Board discussed and noted the 2021 Board Performance Evaluation Results including the actions taken to date to address the feedback received.

    The Minister for Finance and Employee Relations addressed the Board via video conference and discussed with the Board the key issues facing the organisation.

    The Board received an update on the key discussions that took place at the relevant Board Sub-Committees during February, being the Audit and Risk Committee, Investment and Asset Committee and the People and Remuneration Committee.